Traditionally, cancer research has been focused on identifying gene mutations in different types of breast cancer. In contrast, how the epigenetic circuit affects cancers remains poorly characterised.
Epigenetic change: another way to induce cancers
While genetic mutation is a change in one or more parts of the DNA sequence, an epigenetic change also changes a gene’s DNA, but not at the sequence level. Instead, special marks, called epigenetic marks, are added to or removed from the DNA sequence to change how a protein works in the body. And specific epigenetic marks are contained in super-enhancers. Deregulation, meaning abnormal regulation, of super-enhancers can therefore induce high production of cancer driver proteins and promote cancer formation.
To find out how these super-enhancers can affect TNBC cells’ growth, Dr Rebecca Chin Yuet-ming, a cancer biologist, and Dr Wang Xin, a computational biologist, both from the Department of Biomedical Sciences at CityU, joined hands together to lead the study. Their findings were published in the scientific journal Nature Communications, titled “Defining super-enhancer landscape in triple-negative breast cancer by multiomic profiling”.
Integrating multi-level epigenomic sequencing data for 21 cell lines with gene expression data and clinical information for over 4,000 patient samples, Dr Wang’s team used the method of multiomic profiling to perform in-depth data mining and built a specific super-enhancer-target regulatory network for all types of breast cancer.
A key regulator of cancer growth
“Our integrated analyses reveal that the clustering of super-enhancers is sufficient to characterise different subtypes of breast cancer,” said Dr Wang. “Importantly, based on the regulatory network, we identify the gene FOXC1 as a key regulator of cancer growth and metastasis which is driven by a TNBC-specific super-enhancer. The FOXC1 is predictive of patients’ survival and help develop therapeutic strategies targeting epigenetic circuits.”
A number of key cancer driver genes (oncogenes), including FOXC1 and MET, are known to promote cancer growth and are associated with worse survival in TNBC patients. However, very little is known about how these genes being specifically highly expressed in TNBC. “Our network biology analysis uncovers FOXC1 as the master regulator of a large set of genes in metastasis. Using CRISPR/Cas9 technology, we further directly demonstrate that super-enhancer drives FOXC1 expression, and importantly, enhances cancer growth in mouse models,” said Dr Chin.
By performing analysis on in-house clinical samples, the teams also learnt that FOXC1 upregulation is associated with higher tumour grade, cell division rate, and tumour-infiltrating immune cells.
Another TNBC-specific gene
The researchers went a step further and applied the integrated method to discover another new TNBC-specific gene ANLN. ANLN has been shown to be correlated with TNBC recurrence and poor survival rate in previous studies. In this study, the team found that the deletion of super-enhancer of ANLN could reduce the protein expression and tumour cell growth. “These findings demonstrate the power of leveraging epigenetic landscape to identify novel players in TNBC, paving the way to discover more effective therapeutic targets for this aggressive form of breast cancer,” Dr Chin said.
Breast cancer is the most common type of cancer in women, with about 4,600 new cases of breast cancer being diagnosed in Hong Kong each year. Among all breast cancers, TNBC accounts for about 10-15%. Different from other types of breast cancer, TNBC does not express hormone receptors (namely estrogen receptors and progesterone receptors) and a protein called Her2, and that’s where its name “triple-negative breast cancer” comes from. So TNBC is quite “invisible”, and it is also difficult to heal as the scientists have not found an effective “target” on the TNBC cancer cell for the drugs to attack.
TNBC usually develops between the ages of 40-50, younger than the average breast cancer patients. Also, the time for TNBC metastasis is shorter. Patients typically relapse within 5 years of treatment, and is considered to have a poorer prognosis than other breast cancer forms.
“We hope our findings can contribute to the development of effective drugs for TNBC patients to improve their chance of survival,” said Dr Chin.
Huang Hao and Hu Jianyang from CityU’s BMS are the co-first authors of the study. This study exemplified the fruitful multidisciplinary collaborations among research groups at CityU and health institutes. Dr Chan Kui-ming and Dr Zhang Liang from BMS co-authored the study. Scientists from Queen Elizabeth Hospital of Hong Kong and The Affiliated Tumor Hospital of Guangxi Medical University also contributed.
Related story: A biomarker for categorizing colorectal cancer patients